Allogeneic CD19-CAR-NK cells for refractory myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to target and destroy the B cells causing your muscle weakness. It is for people with refractory myasthenia gravis who have not improved enough with standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have moderate to severe muscle weakness (MGFA class II to IV).
- You tested positive for AChR antibodies in your blood.
- You have tried at least two conventional immunosuppressants and one biologic medication (such as efgartigimod, rituximab, or eculizumab) and still have significant symptoms (MG-ADL score of 6 or higher).
- You have been on stable doses of your current medications for at least 1 month (steroids), 3 months (immunosuppressants), or 2 weeks (pyridostigmine) before entering the trial.
- You have not received a live vaccine, certain other biologics, or rescue therapies like plasma exchange or intravenous immunoglobulin within the required time frames before enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called HN2302 for people with generalized myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if HN2302 is safe and helps reduce muscle weakness symptoms.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial tests an experimental cell therapy (UCAR T-cells) that targets two markers on immune cells to treat myasthenia gravis that hasn't improved with standard treatments. It aims to reduce symptoms and improve daily functioning.
Hear when a new Refractory Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.